EUCTR2010-022180-35-DE进行中（未招募）不适用
Ofatumumab in relapsed nodular lymphocyte predominant Hodgkin Lymphoma
niversity of Cologne0 个研究点开始时间: 2011年1月18日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
已完成
2 期
Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)Relapsed NLPHLNCT01187303University of Cologne28
进行中（未招募）
1 期
Study to evaluate the efficacy and safety of a therapy consisting in combination of two drugs Ofatumumab and Ibrutinib followed by bone marrow transplant taken from donor or consolidation for pretreated high risk patients with Chronic Lymphocytic LeukemiaMedDRA version: 21.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864Chronic Lymphocytic LeukemiaEUCTR2015-000684-13-ITFONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS80
进行中（未招募）
1 期
Ofatumumab in patients with lymphoma of the of the mucosa associated lymphoid tissue (MALT-Lymphoma)YMPHOMA OF THE MUCOSA ASSOCIATED LYMPHOID TISSUE (MALT-LYMPHOMA)MedDRA version: 16.0Level: PTClassification code 10061850Term: Extranodal marginal zone B-cell lymphoma (MALT type)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-005223-32-ATMedizinische Universität Wien, Klinik für Innere Medizin I, Abt. Onkologie
进行中（未招募）
不适用
Treatment with Ofatumumab for RElapsed/refractory Splenic B-cell marginal zone lymphoma (MORE)EUCTR2013-004916-23-ITOspedale San Raffaele
已完成
2 期
A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's MacroglobulinemiaWaldenstrom MacroglobulinaemiaNCT00811733GlaxoSmithKline37